Ezetimibe is the selective cholesterol absorption inhibitor. It is indicated for the treatment of primary hypercholesterolemia. The current investigation was aimed to formulate Solid self-emulsifying drug delivery system (S-SEDDS) for Ezetimibe to enhance solubility and dissolution rate which will leads to minimize the variability in absorption and it may enhance oral bioavailability of the poorly soluble drug, ezetimibe. Various modified oils, surfactant, co-surfactant mixtures were screened for their suitability in the formulation of SEDDS and composition of Solid self-emulsifying drug delivery system (S-SEDDS) was optimized. The optimized formulation was added on to an adsorbent, Aerosil 200. The drug release from these optimized formulations was studied and found to be better compared to conventional dosage form. Our studies indicate that Solid-SEDDS can be effectively formulated by adsorption technique. Solid-SEDDS were characterized by X-ray diffraction pattern, DSC, SEM and dissolution profile. It was supported by SEM studies, which did not show evidence of precipitation of the drug on the surface of the carrier. Dissolution studies revealed remarkable increase in dissolution of the drug as compared to marketed product.
